The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027.

Many of us with chronic obstructive pulmonary disease (COPD) have received medical devices to help with our breathing. At first, it seemed to me that some of these devices worked better than others.

Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could help patients manage their condition better - around a quarter ...

This open line of communication led his doctor to prescribe TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder), a once-daily treatment for ...

Trelegy Ellipta got its first US approval in September as a daily long-term maintenance therapy for chronic obstructive pulmonary disease (COPD). Trelegy was approved in Europe last week in COPD ...

The FDA late Monday approved sales of Trelegy Ellipta, developed jointly by GlaxoSmithKline PLC and Innoviva Inc. It contains three widely used types of medicine to prevent — rather than treat ...